Plan B advocates plotting response to FDA delay in OTC approval

Advocates of the "morning after" emergency contraceptive drug are planning a reaction strategy to the FDA's delay of a decision on over-the-counter status for the drug despite an advisory panel's recommendation in December for OTC status. Saying it needed more time to review data, the agency put off a decision, prompting women's and public-health groups to accuse it of yielding to pressure from anti-contraception groups. Meanwhile, the Virginia House of Delegates took a preliminary step in voting to restrict the dispensing of such drugs.

View Full Article in:

Washington Post (tiered subscription model), The · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations